Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed. At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 100
Healthy Volunteers: t
View:

• All patients met the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3).

Locations
Other Locations
China
Qilu Hospital of Shandong University
RECRUITING
Jinan
Contact Information
Primary
haiyun li
haiyunli1122@163.com
18560088921
Backup
wenjing jiang
jiangwenjing@qiluhospital.com
18560082210
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2025-08-26
Participants
Target number of participants: 60
Treatments
narcolepsy group
health control group
Sponsors
Leads: Qilu Hospital of Shandong University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials